Gallbladder Adenocarcinoma Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0031633 (Gallbladder Adenocarcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00142480Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder CancerTreatment
NCT00361231Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder CancerTreatment